Novavax, Inc. (NVAX)
8.525
-0.24
(-2.68%)
USD |
NASDAQ |
Nov 13, 16:00
8.52
0.00 (0.00%)
After-Hours: 19:59
Novavax Enterprise Value : 1.079B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.079B |
| November 12, 2026 | 1.118B |
| November 11, 2026 | 1.320B |
| November 10, 2026 | 1.356B |
| November 09, 2026 | 1.470B |
| November 06, 2026 | 1.452B |
| November 05, 2026 | 1.287B |
| November 04, 2026 | 1.430B |
| November 03, 2026 | 1.270B |
| November 02, 2026 | 1.245B |
| October 30, 2026 | 1.336B |
| October 29, 2026 | 1.400B |
| October 28, 2026 | 1.376B |
| October 27, 2026 | 1.326B |
| October 26, 2026 | 1.224B |
| October 23, 2026 | 1.273B |
| October 22, 2026 | 1.321B |
| October 21, 2026 | 1.489B |
| October 20, 2026 | 1.559B |
| October 19, 2026 | 1.458B |
| October 16, 2026 | 1.531B |
| October 15, 2026 | 1.788B |
| October 14, 2026 | 1.758B |
| October 13, 2026 | 1.788B |
| October 12, 2026 | 1.762B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.777B |
| October 08, 2026 | 1.489B |
| October 07, 2026 | 1.524B |
| October 06, 2026 | 1.541B |
| October 05, 2026 | 1.745B |
| October 02, 2026 | 1.399B |
| October 01, 2026 | 1.422B |
| September 30, 2026 | 1.456B |
| September 29, 2026 | 1.361B |
| September 28, 2026 | 1.358B |
| September 25, 2026 | 1.330B |
| September 24, 2026 | 1.325B |
| September 23, 2026 | 1.317B |
| September 22, 2026 | 1.363B |
| September 21, 2026 | 1.294B |
| September 18, 2026 | 1.244B |
| September 17, 2026 | 1.226B |
| September 16, 2026 | 1.119B |
| September 15, 2026 | 1.099B |
| September 14, 2026 | 1.159B |
| September 11, 2026 | 1.131B |
| September 10, 2026 | 1.111B |
| September 09, 2026 | 1.201B |
| September 08, 2026 | 1.257B |
| September 04, 2026 | 1.262B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 89.30B |
| Merck & Co., Inc. | 408.57B |
| Pfizer Inc. | 213.37B |
| Amgen, Inc. | 292.70B |
| Editas Medicine, Inc. | 214.00M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.38M |
| Revenue (Quarterly) | 68.30M |
| Total Expenses (Quarterly) | 99.67M |
| EPS Diluted (Quarterly) | -0.1902 |
| Gross Profit Margin (Quarterly) | 71.03% |
| Profit Margin (Quarterly) | -45.94% |
| Earnings Yield | -5.47% |
| Normalized Earnings Yield | -4.667 |